Anlotinib Combined With Dose-reduced Olaparib in Patients With Platinum-Sensitive Recurrent Ovarian Cancer

NCT04566952 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

68

Enrollment

OTHER

Sponsor class

Conditions

Ovarian Cancer
Ovarian and Fallopian Tube Cysts and Neoplasms
Neoplasms by Site
Neoplasms
Genital Neoplasms, Female
Urogenital Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Carcinoma, Ovarian Epithelial
Ovarian Diseases
Adnexal Diseases
Genital Diseases, Female
Carcinoma
Anlotinib
PARP Inhibitors
BRCA1 Mutation
Angiogenesis
Antineoplastic Agents
BRCA2 Mutation

Interventions

DRUG: Anlotinib
DRUG: Olaparib

Sponsor

Xiaoxiang Chen